Join to View Full Profile
300 E 66th StNew York, NY 10065
Phone+1 212-639-2000
Fax+1 212-639-2283
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lillian Smyth, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York.
Education & Training
University College of Dublin National Univ SOMClass of 2006
Certifications & Licensure
NY State Medical License 2014 - 2019
Clinical Trials
- AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations Start of enrollment: 2017 Oct 11
Publications & Presentations
PubMed
- 7 citationsImlunestrant with or without Abemaciclib in Advanced Breast Cancer.Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga
The New England Journal of Medicine. 2025-03-27 - 1 citationsNatural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AA...Michele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M Hyman, Natalie Blauvelt
Clinical Cancer Research. 2022-05-13 - 14 citationsAKT mutant allele-specific activation dictates pharmacologic sensitivities.Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, Matthew T Chang, Debyani Chakravarty
Nature Communications. 2022-04-19
Authored Content
- Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined Through AACR Project GENIE, a Clinicogenomic RegistryMarch 2020
Press Mentions
Press Release: Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in CanadaJanuary 11th, 2019
